Dacula, Sittie Alisha A.
HRN: 21-57-61 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/26/2022
CEFOTAXIME 500MG (VIAL)
08/26/2022
09/02/2022
IV
60mg
Q8h
T/c Sepsis Neonatorum
Waiting Final Action
Indication: Empiric Type of Infection: Bloodstream Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes